Natera

Youtube Subscribe

Open: 48.07 Close: 49.0 Change: 0.93

What an AI can tell you about Natera Company Inc Stock before investing.

Are looking for the most relevant information about Natera? Investor spend a lot of time searching for information to make investment decisions in Natera. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Natera are: Natera, health, test, genetic, global, leader, cellfree, and the most common words in the summary are: natera, test, nipt, prenatal, noninvasive, market, stock, . One of the sentences in the summary was: Natera delivered earnings and revenue surprises of 2.14% and 0.83% for the quarter ended …

Concept Map

Semantic Network

Stock Summary

Natera, Inc. develops and commercializes molecular testing services worldwide. Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies, is a non invasive prenatal.

Today's Summary

Natera delivered earnings and revenue surprises of 2.14% and 0.83% for the quarter ended December 2022. Current share price of NASDAQ:NTRA is $87.69. Company raised a total of $151.6M in PIPE and has filed 181 patents.

Today's News

BillionToOne is a global leader in cell-free DNA testing, dedicated to oncology, womens health, and organ health. Natera is proud to be an Equal Opportunity Employer. Associate Clinical Oncology Specialist is responsible for account, service, and support activities of all oncology products. Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncologists, womens health, and organ health. Natera (NASDAQ: NTRA) operates as a clinical genetic testing company. Company raised a total of $151.6M in PIPE and has filed 181 patents. Natera, Inc. estimated fair value is US$87.69 based on 2 Stage Free Cash Flow to Equity. Current share price of NASDAQ:NTRA is $87.9x. Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83% for the quarter ended December 2022. The company is seeing favorable earnings estimate revision activity. The PESTLE analysis of Natera, Inc. analyzes the social, technological, legal, and environmental factors that can affect the companys growth trajectory. With its innovative technology and proprietary algorithms for analyzing large amounts of genetic data. natera panorama test report 567.1K views Discover videos related to nater a panorama report on TikTok. There has been a notable upward trend in the market. Natera Panorama results came back saying high risk for triploidy (which is fatal or “not compatible with life”) Latest:  2 months ago |  Lwilson7887 9 Featured Report as Inappropriate High Risk for TriploidY. Natera aims to make personalized genetic testing and diagnostics part of the standard care to protect health to protect earlier health. The presence of ctDNA at any time was strongly associated with disease recurrence.

Stock Profile

"Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas."

Keywords

This document will help you to evaluate Natera without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Natera are: Natera, health, test, genetic, global, leader, cellfree, and the most common words in the summary are: natera, test, nipt, prenatal, noninvasive, market, stock, . One of the sentences in the summary was: Natera delivered earnings and revenue surprises of 2.14% and 0.83% for the quarter ended December 2022. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #natera #test #nipt #prenatal #noninvasive #market #stock.

Read more →

Youtube Subscribe

---